Pcn487 Cost of Prostate Cancer and Quality of Life in Egypt - A Patient Perspective Study

Abstract

Objectives: To ensure reliable, valid assessments of patients' Health-Related Quality of Life (HRQOL), it is important to use psychometrically robust instruments. In the context of rare diseases, such as metastatic MCC (mMCC), disease-specific instruments are often not available, so instruments from related diseases are used. Previously, the psychometric performance of FACT-M was documented in a cohort of patients with mMCC whose disease progressed after chemotherapy. This study aims to confirm the psychometric performance of FACT-M in patients with mMCC who were either treatment naive or had previously received chemotherapy. Methods: Based on a previously published qualitative analysis, it was confirmed that patients with mMCC, whether treatment naive or previously treated, had similar experiences and concepts associated with their disease. Patient-report outcomes (PRO) data were pooled (n=173) from the single-arm, phase 2 JAVELIN Merkel 200 trial (NCT02155647) from part A (previously treated, n=70) and part B (treatment naive, n=103). Cronbach a was used to assess internal consistency reliability. Convergent validity was assessed using correlations with EQ-5D items. Knowngroups validity was explored using ECOG performance status (PS) 0 vs 1. Results: Cronbach a for all FACT-M scales was excellent, ranging between 0.80 (emotional well-being) and 0.95 (FACT-M total score). As expected, FACT-M subscale scores generally correlated highest with EQ-5D items that measured similar constructs, suggesting good concurrent validity. Known-groups validity analyses showed that the FACT-M differentiated well between ECOG PS 0 and 1. For all subscales, patients with ECOG PS=1 had worse scores compared to ECOG PS=0, with p,0.05 except for social well-being. Conclusions: In the context of rare diseases, which often have limited data available for instrument validation, this analysis confirmed the previously established psychometric performance of FACT-M in patients with mMCC regardless of prior treatment status, reaffirming its suitability for this patient population.

Anatomical characteristics and variant of prostatic artery by digital subtraction angiography relevant to prostatic artery embolization

“…In contrary to the low fatality rate, prostate cancer has a serious influence on the patients quality of life. 11 PAE has showed good results for symptomatic reduction of LUTS problems in people with BPH. One of the hardest things of PAE is to recognize the PAs and distinguishing them from the nearby vasculature.…”

Improvement prostate cancer detection rate of suspicious lesions through MRI/TRUS fusion guided biopsy by a multiteam of radiologists

“…Author details 1 UOC Urologia Ospedale Versilia, Camaiore, LU, Italy. 2 UOC Radiologia Ospedale Versilia, Camaiore, Italy.…”

“…PC is the fourth most common cancer type in Egypt with an incidence rate of about 4.5% among male cancer patients. Despite having Fiorello et al Egypt J Radiol Nucl Med (2022) 53 :5 a low mortality rate, prostate cancer greatly impacts the patients' quality of life [2].…”

“…Multiparametric magnetic resonance imaging (mp-MRI) combining T2-weighted (T2w) imaging with diffusion-weighted (Dw) imaging, dynamic contrast-enhanced (DCE) imaging and/or magnetic resonance spectroscopy (MRS) has yielded promising results in prostate cancer detection and localization [2,3].…”

Assessment of Immunohistochemical Expression of Androgen Receptor and its Correlation with Histopathological Prognostic Factors in Prostatic Carcinoma

“…Prostatic carcinoma is a disease of increasing significance and is the 2nd most commonly diagnosed tumor in men worldwide and is the most common male malignancy in developed countries (1) , with the highest incidence between 70 and 75 years old. Prostatic carcinoma is a growing concern in Egypt and currently ranks as the 4th most common cancer in the country with an incidence rate of about 4.5% among male cancer patients (2) . There are several risk factors affecting PCa, some of which are nonmodifiable (including age, race/ethnicity, family history, and Geography), while others are modifiable (including diet, obesity, smoking, chemical exposures, prostatic inflammation, sexually transmitted infections, and vasectomy) (3) .…”